PerkinElmer

JUNE 7, 2021

Targeted cancer therapy has been a game changer in cancer treatment, significantly improving the survival and quality of life of many patients. Once we could identify these individual cohorts of patients, we found that each cohort had a different response to treatment, and that patients within the same cohort responded similarly,” he said.

Treatment 52

Treatment Clinical Trials Therapies Trials 52

The Pharma Data

DECEMBER 17, 2020

18, 2020 /PRNewswire/ — Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ® prolonged release buprenorphine for the treatment of opioid dependence in adults and adolescents from 16 years of age. LUND, Sweden , Dec. About Buvidal.

Treatment 52

Treatment Clinical Trials International Pharmaceutical Companies 52

PPD

SEPTEMBER 25, 2023

As the clinical trial landscape evolves, drug developers are faced with novel challenges and changes in study recruitment, trial size and structure, and more. Decentralized Trials Digital and decentralized clinical trials  (DCTs) continue to expand and have become a standard solution for drug developers.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

The Pharma Data

MAY 14, 2021

Product Name: Hives Urticaria & Angioedema Treatment Protocol | Cure & Relief. Hives Urticaria & Angioedema Treatment Protocol | Cure & Relief is backed with a 60 Day No Questions Asked Money Back Guarantee. They try every known cure, treatment, and medically accepted idea — yet NOTHING works!

Treatment 52

Treatment Doctors Pharmacy Production 52

The Pharma Data

JANUARY 17, 2021

This coverage provides a minimally invasive treatment alternative for eligible patients. “Not being able to breathe really limits the ability of patients to go about their daily lives, and for those who qualify for the treatment, endobronchial valves can make a big difference.” . CENTER VALLEY, Pa. ,

Treatment 52

Treatment Clinical Trials Trials Disease 52

The Pharma Data

OCTOBER 19, 2020

(NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the Company’s U.S. Phase 2 trial for Berubicin during the first quarter of 2021.”

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Treatment 52

The Pharma Data

JANUARY 20, 2021

21, 2021 /PRNewswire/ — Calliditas Therapeutics AB (publ) (“Calliditas”) (Nasdaq OMX: CALTX) (NASDAQ: CALT) today announced that all 360 patients have been enrolled for the global Phase 3 clinical trial NefIgArd, which investigates the effect of Nefecon® versus placebo in patients with primary IgA nephropathy (IgAN).

Trials 52

Trials Clinical Trials Pharmaceutical Companies Treatment 52

The Pharma Data

NOVEMBER 15, 2020

16, 2020 /PRNewswire/ –: iSTAR Medical , a medtech company developing minimally invasive ophthalmic implants for treatment of patients with glaucoma, today announced positive one-year results from the European STAR-II clinical trial of its micro-invasive glaucoma surgery (MIGS) device, MINIject TM. WAVRE, Belgium , Nov.

Trials 52

Trials Clinical Trials Engineering Treatment 52

The ChEMBL-og

MARCH 8, 2023

ChEMBL contains information on drugs that have been approved for treatment of a specific disease / diagnosis (an indication) within a region of the world (e.g. FDA drugs are approved for use in the United States), and clinical candidate drugs that are being investigated for an indication during the clinical trials process.

Clinical Trials 40

Clinical Trials FDA Approval Trials Treatment 40

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) has granted orphan drug designation status to APX005M for the treatment of esophageal and gastroesophageal junction cancer and for the treatment of pancreatic cancer. Additional information on clinical trials for APX005M can be found at www.clinicaltrials.gov. SAN CARLOS, Calif. ,

Treatment 40

Treatment Immune Response Clinical Trials Clinical Development 40

Agency IQ

JUNE 28, 2024

New guidance provides definition for orphan device, offers alternative trial designs New guidance from the European Commission outlines alternatives for full pre-market clinical trials for orphan devices, defined by the Commission for the first time.

Trials 40

Trials Marketing Clinical Trials Regulations 40

The Pharma Data

OCTOBER 16, 2020

As pharma companies search for solutions to avoid cancelling or delaying clinical trials, virtualizing trials are fast becoming commonplace during the Covid-19 pandemic. With many nationwide and regional lockdowns coming into force, virtual clinical trials are proving to be an effective way to monitor patients remotely.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Clinical Research 52

The Pharma Data

OCTOBER 25, 2020

for the treatment of severe vernal keratoconjunctivitis (VKC) in patients ages 4-18. “We look forward to working with the FDA during the review process and are optimistic this treatment could provide much needed symptom relief for those affected so they may better engage in their daily activities.” .

Treatment 52

Treatment FDA Pharmaceuticals Clinical Trials 52

The Pharma Data

JANUARY 13, 2021

Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under FDA and EMA. View original content to download multimedia: [link]. . NEW YORK , Jan. MindMed Co-CEO J.R.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

The Pharma Data

OCTOBER 19, 2020

is pleased to announce approval from Health Canada to proceed to a Phase 1 clinical trial with its lead asset, a long-acting anesthetic formulation for the treatment of post-surgical pain. View original content to download multimedia: [link]. TORONTO , Oct. 20, 2020 /PRNewswire/ – AmacaThera Inc. SOURCE AmacaThera Inc.

Clinical Trials 40

Clinical Trials Trials Small Molecule Production 40

The Pharma Data

OCTOBER 27, 2020

Stargardt disease is a devastating genetic disorder that affects central vision with no approved treatment options. . “This designation permits reVision to further accelerate the development of our Stargardt disease treatment. . View original content to download multimedia: [link].

Disease 52

Disease Treatment FDA Licensing 52

PPD

OCTOBER 12, 2023

These treatments use a vector to introduce the desired nucleic acid code to replace or modify protein expression or use cells to alter/restore a specific cell type. There are over 2,000 CGTs currently being evaluated in clinical trials, with more than 200 in Phase III and 10-20 per year estimated to come to market by 2025.

Laboratories 52

Laboratories Protein Expression Clinical Trials Pharmacokinetics 52

The Pharma Data

JUNE 26, 2021

The EUA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalised patients. Roche-sponsored global trials included the placebo-controlled EMPACTA, COVACTA and REMDACTA studies. About the Actemra/RoActemra COVID-19 Clinical Trial Programme.

FDA 40

FDA Treatment Clinical Trials Virus 40

The Pharma Data

SEPTEMBER 11, 2020

In an effort to slow the spread of the disease and prevent a second wave, pharma companies around the world are continuously looking to advance new methods of treatment. DEP remdesivir enables subcutaneous or under the skin injections rather than intravenous infusion, allowing for outpatient treatments and reducing the burden on hospitals.

Clinical Trials 52

Clinical Trials Pharma Companies Trials Hospitals 52

The Pharma Data

MAY 14, 2021

Product Name: Fast Shingles Cure – The #1 Shingles Treatment Method Available. Fast Shingles Cure – The #1 Shingles Treatment Method Available is backed with a 60 Day No Questions Asked Money Back Guarantee. combination of treatments to cure Shingles as fast as. treatments. sufferers to finally find the right.

Treatment 52

Treatment Doctors Virus Vaccine 52

The Pharma Data

DECEMBER 22, 2020

Approximately 74 patients are planned for this trial in Head and Neck Squamous Cell Carcinoma (HNSCC) and Cutaneous Squamous Cell Carcinoma (CuSCC). The trial will enroll three cohorts of patients within distinct populations – all with locally advanced, recurrent and/or metastatic HNSCC or locally advanced or metastatic CuSCC.

Clinical Trials 52

Clinical Trials Therapies Trials Production 52

The Pharma Data

DECEMBER 16, 2020

The Company will initiate its trial during the first quarter of 2021 to investigate the efficacy of Berubicin in adults with GBM who have failed first-line therapy. and 2 trials planned by our sublicensee WPD in Poland. . and 2 trials planned by our sublicensee WPD in Poland.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

The Pharma Data

NOVEMBER 25, 2020

26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. LUND, Sweden , Nov. About Cantargia.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

KIF1A

AUGUST 28, 2024

We also extend our deepest gratitude to n-Lorem for creating and providing the ASO drug that made this trial possible. And most importantly, our utmost respect and appreciation go to the pioneering family and patient who courageously participated in this trial. Together, we are making history and bringing hope to the KAND community!

Therapies 52

Therapies Compound Screening Research Treatment 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) has approved WAKIX® (pitolisant) for the treatment of cataplexy in adult patients with narcolepsy. WAKIX is the first and only treatment approved by the FDA for people with excessive daytime sleepiness or cataplexy associated with narcolepsy that is not scheduled as a controlled substance by the U.S.

FDA Approval 52

FDA Approval FDA Treatment Clinical Trials 52

The Pharma Data

SEPTEMBER 27, 2021

Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma (B-NHL) Published within the Lancet. the security , antitumor activity, and immune biomarkers related to epcoritamab treatment were assessed.1. Chief military officer of Genmab.

Trials 40

Trials Treatment Clinical Trials International 40

The Pharma Data

JANUARY 17, 2021

plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields. SEOUL, South Korea , Jan. FDA this year.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

The Pharma Data

JANUARY 6, 2021

7, 2021 /PRNewswire/ — UNION therapeutics A/S ( UNION ) today announces that the US Food and Drug Administration (FDA) has approved an Investigational New Drug program (IND) for oral orismilast; a next generation PDE4-inhibitor for the treatment of plaque psoriasis in adults. One step closer to a novel treatment.

FDA Approval 52

FDA Approval FDA Clinical Development Clinical Research 52

The Pharma Data

JANUARY 31, 2021

The practice offers standard and advanced therapeutics including chemotherapy, biologic therapy immunotherapies and radiopharmaceuticals along with a total complement of radiation oncology treatment options, including proton therapy, brachytherapy, and radiosurgery. View original content to download multimedia: [link]. Source link.

Clinical Trials 52

Clinical Trials Therapies Trials Treatment 52

The Pharma Data

OCTOBER 19, 2020

Caris’ collaborative network focused on expanding the application of precision medicine in oncology supports Winship’s enterprising approach to research leading to transformative discoveries in cancer care and treatment. The NCTN serves as the NCI’s primary infrastructure to conduct phase II and III clinical trials.

Clinical Trials 52

Clinical Trials RNA DNA Science 52

The Pharma Data

JANUARY 6, 2021

Quantitative imaging of CD8 T cells enables quicker identification of drug efficacy, therefore potentially reducing the length of clinical trials, reducing costs and helping new therapies to advance to market faster, which ultimately will improve treatment and care of cancer patients. SOURCE ImaginAb, Inc. Source link.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

The Pharma Data

DECEMBER 28, 2020

Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft tissue sarcomas. .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

DECEMBER 14, 2020

In Covid-19, Rabeximod is positioned as an oral treatment of moderately diseased patients – a group that is not addressed by current standard of care therapeutics. It is a quality stamp on our drug candidate and Covid-19 trial and would enable us to expand the clinical development to the United States. SOURCE Cyxone.

FDA 52

FDA Clinical Trials Clinical Development Treatment 52

The Pharma Data

JANUARY 22, 2021

Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ Lupkynis TM (voclosporin) as the first oral treatment developed specifically for adults with active lupus nephritis (LN) in combination with standard of care. NEW YORK , Jan.

Research 52

Research Treatment FDA Approval Disease 52

The Pharma Data

JANUARY 19, 2021

The event will feature a presentation by renowned lymphoma expert Mats Jerkeman, MD, Lund University, who will discuss the current treatment landscape, and unmet medical need for patients with relapsed or refractory Non-Hodgkin’s Lymphoma for whom current treatment options are very limited. SOURCE BioInvent. Source link.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

JANUARY 27, 2021

“The responses observed in six out of nine patients are very encouraging and clearly suggest that BI-1206 may restore the response to rituximab in patients who have few treatment alternatives. . (Nasdaq: CASI), a U.S. CEO of BioInvent. CEO of BioInvent. Wei-Wu He , Ph.D.,

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 16, 2020

Last year, GSK announced positive results from a two-year clinical trial involving several hundred people with active lupus nephritis treated with Benlysta. Effective treatment can greatly improve health outcomes and reduce the long-term costs associated with managing lupus-related kidney disease.”

FDA Approval 52

FDA Approval FDA Clinical Trials Treatment 52